GYRE THERAPEUTICS, INC. — Filing Summary
Important issuer mismatch: The supplied filing is Targacept, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, not a filing identified as Gyre Therapeutics, Inc. Confirm the issuer and filing before relying on this summary.
Business context and reporting period
Targacept was a clinical-stage biopharmaceutical company developing neuronal nicotinic receptor (NNR) therapies. This annual report covers the year ended December 31, 2013; it also provides unaudited quarterly results, including fourth-quarter 2013. The company reported no current product revenue and had closed its laboratory operations in 2012.
Key financial metrics
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Net operating revenue | $3.6 million | $57.9 million |
| Research and development expense | $38.8 million | $49.1 million |
| General and administrative expense | $12.0 million | $13.2 million |
| Operating loss | $47.2 million | $8.1 million |
| Net loss | $46.7 million | $7.0 million |
| Basic and diluted loss per share | $1.39 | $0.21 |
| Cash used in operating activities | $40.6 million | $64.2 million |
Revenue was primarily collaboration-related, not product sales. The 2013 revenue decline mainly reflected the absence of the large deferred-revenue recognition recorded in 2012 for the terminated TC-5214/AstraZeneca MDD collaboration. Targacept recognized the remaining deferred revenue associated with TC-1734 in 2013; it said previously deferred collaboration amounts had been fully recognized by year-end. Operating margins are not a meaningful measure for this development-stage, loss-making business.
At December 31, 2013, cash, cash equivalents and investments totaled $143.8 million, down from $184.9 million a year earlier. Working capital was $82.6 million; total assets were $145.9 million and stockholders’ equity was $134.6 million. Total debt was approximately $1.1 million ($853,000 current and $283,000 long-term). The company reported an accumulated deficit of $280.6 million. Fourth-quarter 2013 revenue was $93,000 and net loss was $13.4 million, or $0.40 per share.
Material changes versus prior periods
- Revenue fell $54.2 million year over year, while net loss widened by $39.7 million. Lower collaboration revenue more than offset reduced operating expenses.
- R&D expense decreased $10.2 million, principally due to the 2012 workforce reductions, laboratory closure and completion of the MDD program; increased spending on the TC-5214 overactive-bladder trial partly offset those savings.
- Operating cash use improved by $23.6 million year over year, mainly reflecting lower R&D and administrative cash outlays. Cash and investments nevertheless declined by $41.2 million.
- TC-5619’s Phase 2b schizophrenia trial, completed in December 2013, did not meet its primary or key secondary measures. The company said it had no plans for further development in that indication.
- AstraZeneca terminated its TC-1734 rights in 2013, and those rights reverted to Targacept. Targacept became responsible for the ongoing Alzheimer’s trial and any future development and commercialization.
Outlook, risks and unusual items
- Management expected existing capital resources to fund operations through at least the end of 2015, while cautioning that plans could change and additional funding might be needed sooner. It expected 2014 R&D expense and operating cash payments to decrease, principally following completion of the TC-5619 schizophrenia trial.
- TC-5214 was in a Phase 2b overactive-bladder trial designed for approximately 750 patients. The company had not yet established clinical efficacy in that indication.
- TC-1734 was in a Phase 2b mild-to-moderate Alzheimer’s trial comparing it with donepezil, with results anticipated in mid-2014. The filing notes that the trial’s SPA does not guarantee approval and that the study alone would not be sufficient for approval. Additional testing could be delayed by the need to manufacture more drug supply.
- TC-6499’s exploratory Phase 2a diabetic-gastroparesis study was planned for mid-2014. Previous TC-6499 results in another gastrointestinal condition missed the primary endpoint.
- AstraZeneca controlled key development decisions for AZD1446. Targacept could receive contingent milestones and royalties, but said it did not expect the collaboration to be a significant source of future funds; future payments were uncertain.
- The company had an effective shelf registration for up to $200 million of common stock and an at-the-market sales agreement for up to $40 million, creating potential dilution. Contractual obligations totaled $20.6 million, including $18.7 million of purchase obligations, largely tied to development-related services and supplies.
- Key risks included clinical-trial failure or delay, dependence on third-party collaborators and manufacturers, limited pipeline replenishment after laboratory closure, patent and regulatory uncertainty, and the possibility that adequate reimbursement or market acceptance would not follow any approval. No material pending legal proceedings were reported. The auditor issued an unqualified opinion and reported effective internal control over financial reporting.
Important facts for investors to verify
- Confirm that this Targacept 2013 10-K is the intended filing; it does not identify Gyre Therapeutics as the registrant.
- Check subsequent results and regulatory developments for the TC-5214 and TC-1734 trials, and whether the planned TC-6499 study began.
- Verify current cash, investment balances, operating burn and the basis for the stated runway through at least year-end 2015.
- Review AstraZeneca’s subsequent development decisions for AZD1446 and any resulting milestone or royalty prospects.
- Assess actual use of the shelf or ATM facility, share dilution, and the timing and nature of the disclosed purchase obligations.